Coverage
-
October 12, 2022
Novartis unit Sandoz is continuing its fight against the U.S. Food and Drug Administration's decision to give exclusivity to a Sanofi multiple sclerosis drug, saying at the D.C. Circuit that the agency's decision was "legally unsupportable."
2 other articles on this case.
View all »